Green Planet Bioengineering Co Ltd (GPLB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Green Planet Bioengineering Co Ltd (GPLB) trades at $0.01. Green Planet Bioengineering Co. Ltd. is a shell company focused on acquiring and merging with an existing business. Market cap: $260,083, Sector: Financial services.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for GPLB: GPLB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GPLB against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GPLB: 1/1 perspectives are bearish.
How is this calculated? →Green Planet Bioengineering Co Ltd (GPLB) Financial Services Profile
Green Planet Bioengineering Co. Ltd., established in 2006, functions as a shell company seeking acquisition and merger opportunities within the financial services sector. Currently without active operations, GPLB aims to identify and integrate with an existing business, presenting a high-risk, high-reward profile for investors.
What Is the Investment Thesis for GPLB?
Investing in Green Planet Bioengineering Co. Ltd. (GPLB) is highly speculative, given its status as a shell company with no current operations. The potential upside lies in the company's ability to successfully acquire and merge with a promising business, which could drive significant value creation. However, the lack of current revenue, a negative P/E ratio of -10.58, and a negative beta of -1.15 indicate substantial risk. Investors should carefully consider the potential for dilution, the uncertainty surrounding the acquisition target, and the overall speculative nature of this investment. The company's success is entirely dependent on its future acquisition strategy.
Based on FMP financials and quantitative analysis
GPLB Key Highlights
- Green Planet Bioengineering Co. Ltd. operates as a shell company, focusing on mergers and acquisitions within the financial services sector.
- The company's market capitalization is $0.00B, reflecting its current lack of operational activity.
- GPLB's P/E ratio is -10.58, indicating negative earnings and the absence of profitability.
- The company's beta is -1.15, suggesting an inverse correlation with market movements and potentially lower volatility compared to the broader market.
- Green Planet Bioengineering does not offer a dividend, consistent with its status as a shell company focused on future acquisitions.
Who Are GPLB's Competitors?
GPLB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMLTF AMP Limited | $1.05 | +0.00% | $2.55B | 62 |
| PHLLF Petershill Partners PLC | $4.13 | +0.07% | $4.47B | 59 |
| APLMW Apollomics, Inc. | $0.02 | +15.15% | $280.82M | 59 |
| ACOG Alpha Cognition Inc. | $7.96 | +0.89% | $123.63M | 58 |
| BAYAU Bayview Acquisition Corp Unit | $12.00 | +4.17% | $63.12M | 47 |
| RANG Range Capital Acquisition Corp. | $10.70 | +0.05% | $171.52M | 48 |
| ACAAU Averin Capital Acquisition Corp. Units | $10.12 | +0.00% | $289.29M | 48 |
| SBXE-UN SilverBox Corp V | $10.15 | +0.00% | $243.60M | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GPLB's Key Strengths?
- Clean slate with no legacy issues.
- Flexibility to pursue various acquisition targets.
- Potential for significant value creation through a successful acquisition.
- Existing public listing provides access to capital markets.
What Are GPLB's Weaknesses?
- No current revenue or operations.
- High dependence on management's ability to identify and execute a successful acquisition.
- Significant uncertainty regarding the future direction of the company.
- Potential for dilution through future equity offerings.
What Could Drive GPLB Stock Higher?
- Announcement of a potential acquisition target, which could drive investor interest and increase the stock price.
- Efforts to identify and evaluate potential acquisition opportunities.
- Changes in market conditions that make acquisitions more attractive.
What Are the Key Risks for GPLB?
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Failure to identify a suitable acquisition target, which could lead to the company's dissolution.
- Unsuccessful integration with the acquired business, resulting in financial losses.
- Limited financial disclosure and lack of regulatory oversight.
- Low liquidity and high price volatility.
- Dilution of existing shareholders through future equity offerings.
What Are the Growth Opportunities for GPLB?
- Acquisition of a Fintech Company: Green Planet Bioengineering could target a rapidly growing fintech company to capitalize on the increasing demand for digital financial services. The global fintech market is projected to reach $697.5 billion by 2030, growing at a CAGR of 23.42% from 2023. A successful acquisition in this space would provide GPLB with immediate revenue streams and a strong growth trajectory.
- Merger with a Sustainable Investment Firm: Given the increasing focus on ESG investing, Green Planet Bioengineering could merge with a sustainable investment firm. The global ESG investing market is expected to reach $41 trillion by 2022. This merger would allow GPLB to tap into a growing market segment and attract socially responsible investors.
- Acquisition of an Asset Management Company: Green Planet Bioengineering could acquire an asset management company to generate stable revenue through management fees. The global asset management market is projected to reach $147.6 trillion by 2025. This acquisition would provide GPLB with a diversified portfolio of assets and a steady income stream.
- Merger with a Blockchain Technology Company: Green Planet Bioengineering could merge with a blockchain technology company to leverage the growing adoption of blockchain in financial services. The global blockchain market is projected to reach $39.7 billion by 2025. This merger would position GPLB at the forefront of technological innovation in the financial sector.
- Acquisition of a Specialty Finance Company: Green Planet Bioengineering could acquire a specialty finance company focused on niche lending markets. These companies often generate higher margins due to reduced competition and specialized expertise. This acquisition would allow GPLB to diversify its revenue streams and target underserved market segments.
What Opportunities Does GPLB Have?
- Acquire a high-growth business in a rapidly expanding market.
- Merge with a company with complementary strengths and synergies.
- Capitalize on undervalued assets or distressed businesses.
- Attract strategic investors to support future growth.
What Threats Does GPLB Face?
- Inability to identify a suitable acquisition target.
- Failure to successfully integrate with the acquired business.
- Increased competition from other shell companies and investment firms.
- Changes in market conditions or regulatory environment.
What Are GPLB's Competitive Advantages?
- As a shell company, Green Planet Bioengineering Co. Ltd. does not currently possess a traditional economic moat.
- The company's potential moat will depend on the competitive advantages of the business it acquires.
- Potential moats could include proprietary technology, brand recognition, or a strong market position.
What Does GPLB Do?
Green Planet Bioengineering Co. Ltd. was founded on October 30, 2006, and is headquartered in Aventura, Florida. The company's primary purpose is to identify, acquire, and merge with an existing operating business. As a shell company, Green Planet Bioengineering currently does not have any active business operations or generate revenue. The company's strategy revolves around finding a suitable target for acquisition, which would then allow it to enter a specific market or industry. The success of Green Planet Bioengineering hinges on its ability to identify and successfully integrate with a viable business. The company's future direction and market positioning are entirely dependent on the nature of the business it ultimately acquires.
What Products and Services Does GPLB Offer?
- Green Planet Bioengineering Co. Ltd. functions as a shell company.
- The company seeks to acquire an existing business operation.
- GPLB aims to merge with the acquired business.
- The company is currently not engaged in active business operations.
- GPLB's primary activity is identifying potential acquisition targets.
- The company intends to use the acquisition to enter a specific market or industry.
How Does GPLB Make Money?
- Green Planet Bioengineering's business model is centered around identifying and acquiring an existing operating company.
- The company intends to merge with the acquired entity to create a new business operation.
- GPLB's revenue model will depend on the business it ultimately acquires.
What Industry Does GPLB Operate In?
Green Planet Bioengineering Co. Ltd. operates within the financial conglomerates industry, a segment characterized by companies that hold a variety of investments and businesses across different sectors. The industry is influenced by macroeconomic trends, regulatory changes, and investor sentiment. As a shell company, GPLB's success depends on its ability to navigate this landscape and identify a suitable acquisition target. The competitive landscape includes other shell companies and investment firms seeking similar opportunities. The company's future performance is tied to its ability to execute a successful merger or acquisition strategy.
Who Are GPLB's Key Customers?
- As a shell company, Green Planet Bioengineering Co. Ltd. does not currently have customers.
- The company's future customer base will depend on the nature of the business it acquires.
- Potential customers could include businesses or consumers depending on the acquired entity's operations.
Net sellingInsider Activity
The most recent 5 insider filings for Green Planet Bioengineering Co Ltd break down as 5 sales and 0 purchases. On net that is roughly 935K shares disposed (about $351K), a signal worth weighing alongside the fundamentals.
GPLB Valuation & Market Position
With a 260K market cap, Green Planet Bioengineering Co Ltd sits in the micro-cap segment of the market.
ROE 8%Key Financial Metrics
Return on equity for Green Planet Bioengineering Co Ltd stands at 8.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -15.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 0/9Financial Health
Green Planet Bioengineering Co Ltd's Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Green Planet Bioengineering Co Ltd operates in the Financial - Conglomerates industry within the Financial Services sector. It is headquartered in Aventura, US. The company is led by CEO Jordan Weingarten. GPLB has traded publicly since 2012.
GPLB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence from those closest to the company, suggesting they believe the stock is undervalued.
- Positive community sentiment indicates growing belief in GPLB's long-term vision and potential.
- Market perception suggests increasing recognition of GPLB's role in sustainable bioengineering solutions.
- Bullish community views highlight the company's innovative approach and potential for future growth, creating a positive feedback loop.
Bear Case
- Limited publicly available information raises concerns about transparency and potential risks.
- Bearish community views express skepticism regarding the company's ability to scale its operations effectively.
- Recent market developments may introduce new competitive pressures, potentially impacting GPLB's market share.
- Community sentiment reveals worries about potential regulatory hurdles and their impact on the company's future prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GPLB Latest News
No recent news available for GPLB.
GPLB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GPLB.
Price Targets
Wall Street price target analysis for GPLB.
GPLB MoonshotScore
What does this score mean?
The MoonshotScore rates GPLB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jordan Weingarten
CEO
Jordan Weingarten serves as the CEO of Green Planet Bioengineering Co. Ltd. His background includes experience in financial management and corporate strategy. He has been involved in various investment and business development projects. His expertise lies in identifying and evaluating potential business opportunities, structuring deals, and managing financial resources. Weingarten's leadership is focused on guiding Green Planet Bioengineering through its acquisition and merger strategy.
Track Record: Jordan Weingarten's track record includes overseeing the company's efforts to identify and evaluate potential acquisition targets. His strategic decisions have focused on positioning the company for a successful merger or acquisition. Under his leadership, Green Planet Bioengineering has been actively exploring opportunities in various sectors. His experience in financial management is crucial for navigating the complexities of the acquisition process.
GPLB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Green Planet Bioengineering Co. Ltd. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and trading activity may be thin. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is generally reserved for companies with distressed financials, limited operating history, or those that are not current in their reporting obligations.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the difficulty of assessing the company's true financial condition.
- Low Liquidity: Limited trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for Fraud or Manipulation: The OTC Other tier is subject to less regulatory oversight, increasing the risk of fraudulent activity.
- Going Concern Risk: Companies in this tier may have significant financial challenges and a high risk of bankruptcy.
- Shell Company Risk: As a shell company, GPLB's value is entirely dependent on a future acquisition, which may not occur or may not be successful.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the management team's experience and track record.
- Research the company's potential acquisition targets.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and filings for any updates.
- Presence of a CEO and management team.
- Company registration and legal compliance.
- Active efforts to identify acquisition targets.
- Publicly traded status provides some level of transparency.
- Engagement with investors and stakeholders.
Green Planet Bioengineering Co Ltd Financial Services Stock: Key Questions Answered
What does Green Planet Bioengineering Co Ltd do?
Green Planet Bioengineering Co. Ltd. operates as a shell company, meaning its primary purpose is to acquire or merge with an existing business. Currently, GPLB has no active business operations and generates no revenue. The company's value is entirely dependent on its ability to identify and successfully integrate with a viable business. This makes it a highly speculative investment, as its future direction and market positioning are contingent upon a successful acquisition.
What do analysts say about GPLB stock?
As of 2026-03-17, there is no available analyst coverage for Green Planet Bioengineering Co. Ltd. given its status as a shell company with no active operations. Key valuation metrics such as revenue, earnings, and cash flow are not applicable in its current state. Any potential future valuation will depend entirely on the nature and performance of the business it eventually acquires. Investors should conduct their own thorough due diligence and consider the high-risk nature of this investment.
What are the main risks for GPLB?
The main risks for Green Planet Bioengineering Co. Ltd. stem from its status as a shell company. These include the risk of failing to identify a suitable acquisition target, unsuccessful integration with an acquired business, limited financial disclosure, low liquidity, and potential dilution of existing shareholders. Additionally, the company operates on the OTC Other tier, which carries increased risks of fraud and manipulation due to less regulatory oversight. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for GPLB?
Evaluate GPLB on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does GPLB data refresh on this page?
GPLB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GPLB's recent stock price performance?
Green Planet Bioengineering Co Ltd (GPLB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Clean slate with no legacy issues. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GPLB overvalued or undervalued right now?
Valuing Green Planet Bioengineering Co Ltd (GPLB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GPLB?
Before investing in Green Planet Bioengineering Co Ltd (GPLB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the nature of the company.
- AI analysis is pending and may provide additional insights.